Anlotinib and Platinum-etoposide Treatment for Extensive-stage Small-cell Lung Cancer

This clinical trial is about testing the safety and effectiveness of a combination treatment for extensive-stage small-cell lung cancer. The treatment combines Anlotinib with Platinum-etoposide, and is given to patients who have not received any prior systematic chemotherapy or immunity checkpoint inhibitors therapy. The trial is specifically for adults aged 18-70 years with a confirmed diagnosis of extensive-stage small-cell lung cancer, who have not received previous systemic treatment for their condition and have an expected survival time of at least 3 months. The goal of this study is to find a new treatment option that could potentially improve the care and outcomes for patients with this type of lung cancer. During the trial, participants receive the combination treatment according to a specific schedule. The study measures the results by looking at two main outcomes: the objective response rate (ORR) and progression-free survival (PFS). The objective response rate refers to the proportion of patients who show a significant reduction in tumor size, while progression-free survival measures the length of time during and after the treatment that a patient lives with the disease but it does not get worse.